Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  yttrium Y 90 ibritumomab tiuxetan
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
Rituximab and Ibritumomab Tiuxetan in Treating Patients With Stage II-III Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 7306, NCI-2010-02131, NCT01207765
Bendamustine Hydrochloride and Rituximab Followed by Radiolabeled Monoclonal Antibody in Treating Patients With Untreated Follicular Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D1015, NCI-2011-03398, NCT01234766
PET-Directed Therapy in Treating Patients with Limited-Stage Diffuse Large B-Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1001, NCI-2011-02673, CDR0000700624, SWOG-S1001, NCT01359592
Ibritumomab Tiuxetan, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00032517, NCI-2013-00519, NCT01497275
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: BIDMC-2004P-000044, NCI-2011-02445, NCT00110149
Start Over